Добро пожаловать
Зарегистрировать аккаунт
Войдите, используя email
Зарегистрируйтесь с помощью email
Проверь свои входящие
GlobeImmune
About
GlobeImmune focused on developing products for the treatment of cancer and infectious diseases based on our proprietary Tarmogen® platform.
- 11 - 50
Details
- Last Funding Type
- Series C
- Last Funding Money Raised
- $41.20M
- Industries
- Biotechnology,Medical,Therapeutics
- Founded date
- Jan 1, 1995
- Number Of Employee
- 11 - 50
- Operating Status
- Active
GlobeImmune, operates as a biopharmaceutical company. It engages in developing and manufacturing Tarmogens, a targeted molecular immunotherapy for the treatment of cancer and infectious diseases. Its products include GI-3000, a Tarmogen for epidermal growth factor receptor over expressing tumors; GI-4000, a Tarmogen for mutated-Ras mediated cancers; GI-5005, a Tarmogen for chronic hepatitis C infection; GI-8000, a Tarmogen for influenza; and GI-10000 Targeted Ablation of Mutational Escape, a novel use of the Tarmogen platform that eliminates or prevents the emergence of mutated escape variants in patients receiving antiviral or targeted cancer therapies. GlobeImmune was founded in 1995 as Ceres Pharmaceuticals, Inc. The company is based in Louisville, Colorado.
Funding Rounds
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Jan 19, 2010 | Series E | $17.50M | 2 |
Generali Financial Holding
|
— | Detail |
| Sep 26, 2007 | Series C | $41.20M | 3 | — | — | Detail |
Investments
Investors
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
Generali Financial Holding
|
Yes | Series E |
BSI SA
|
— | Series E |
BNY Mellon
|
— | Series C |
|
|
— | Series C |
|
|
— | Series C |
